

Folic Acid for the Prevention of Neural Tube Defects: Recommendation Statement

► See related Putting Prevention into Practice on page 1533.

This summary is one in a series excerpted from the Recommendation Statements released by the U.S. Preventive Services Task Force (USPSTF). These statements address preventive health services for use in primary care clinical settings, including screening tests, counseling, and preventive medications.



This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). See CME Quiz on page 1461.

A collection of USPSTF recommendation statements reprinted in *AFP* is available at <http://www.aafp.org/afp/uspstf>.

The complete version of this statement, including supporting scientific evidence, evidence tables, grading system, members of the USPSTF at the time this recommendation was finalized, and references, is available on the USPSTF Web site at <http://www.uspreventiveservicestaskforce.org/>.

Summary of Recommendation and Evidence

The U.S. Preventive Services Task Force (USPSTF) recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 mcg) of folic acid (Table 1). **A recommendation.**

Rationale

Importance. Approximately one in every 1,000 pregnancies is affected by a neural tube defect.

Recognition of risk status. Although a personal or family history of a pregnancy affected by a neural tube defect is associated with an increased risk of having an affected pregnancy, most cases occur in the absence of any positive history.

Benefits of preventive medication. The USPSTF found convincing evidence that supplements containing 0.4 to 0.8 mg (400 to 800 mcg) of folic acid in the periconceptional period reduce the risk of neural tube defects.

Harms of preventive medication. Adequate evidence suggests that folic acid from supplementation at usual doses is not associated with serious harms.

USPSTF assessment. The USPSTF concludes that, for women who are planning or capable of pregnancy, there is high certainty that the net benefit is substantial.

Clinical Considerations

Patient population. This recommendation applies to women who are planning or capable

Table 1. Folic Acid for the Prevention of Neural Tube Defects: Clinical Summary of the U.S. Preventive Services Task Force Recommendation

Population	Women planning a pregnancy or capable of becoming pregnant
Recommendation	Take a daily vitamin supplement containing 0.4 to 0.8 mg (400 to 800 mcg) of folic acid. Grade: A
Risk assessment	Risk factors include: <ul style="list-style-type: none">• Personal or family history of a pregnancy affected by a neural tube defect• Use of certain antiseizure medications• Mutations in folate-related enzymes• Maternal diabetes mellitus• Maternal obesity <p>NOTE: This recommendation does not apply to women who have had a previous pregnancy affected by neural tube defects, or women taking certain antiseizure medications. These women may be advised to take higher doses of folic acid.</p>
Timing of medication	Start supplementation at least one month before conception; continue through the first two to three months of pregnancy.
Recommendations of others	The American Congress of Obstetricians and Gynecologists, the American Academy of Family Physicians, and most other organizations recommend 4 mg (4,000 mcg) of folic acid supplementation per day for women with a history of a pregnancy affected by a neural tube defect.

NOTE: For the full recommendation statement and supporting documents, visit <http://www.uspreventiveservicestaskforce.org>.

of pregnancy, but it does not apply to women who have had a previous pregnancy affected by neural tube defects or women taking certain antiepileptic medications. Most organizations recommend that these women take higher doses of folic acid.

Assessment of risk. The use of certain antiepileptic medications and a personal or family history of neural tube defects are well-established risk factors. Other reported risk factors include mutations in folate-related enzymes, maternal diabetes mellitus, and obesity.

Timing. Most studies indicate the need to start daily folic acid supplementation at least one month before conception and to continue through the first two to three months of pregnancy. Studies also indicate that 50 percent of pregnancies in the United States are unplanned, and therefore, clinicians should advise all women who are capable of pregnancy to take folic acid supplements.

Dosage. Good evidence from randomized trials in settings without fortification

of food suggests that a multivitamin with 0.8 mg (800 mcg) of folic acid reduces the risk of neural tube defects. Observational studies done before fortification report a reduction of neural tube defects in women taking a supplement with 0.4 mg (400 mcg) of folic acid (the generally available dose). Evidence indicates that most women in the United States are not ingesting fortified foods at a level thought to provide optimal benefit. In a setting in which food is fortified with folic acid, the effective amount of additional folic acid supplementation is unclear.

This recommendation statement was first published in *Ann Intern Med.* 2009;150(9):626-631.

The "Discussion" and "Recommendations of Others" sections of this recommendation statement are available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspnsrnfol.htm>

The U.S. Preventive Services Task Force recommendations are independent of the U.S. government. They do not represent the views of the Agency for Healthcare Research and Quality, the U.S. Department of Health and Human Services, or the U.S. Public Health Service. ■

Cost-Effectiveness Analysis of Treatment Options for Acute Otitis Media

ABSTRACT

Background: The costs and utility of observation and routine antibiotic treatment compared with delayed prescription, 5 days of antibiotic treatment, and 10 days of antibiotic treatment were compared in a Markov model. The model included the costs of observation, antibiotic treatment, and lost workdays. The utility of observation and antibiotic treatment was based on the quality-adjusted life expectancy (QALE) of patients. The model was run for 100,000 patients. The results show that observation was the most cost-effective treatment option for acute otitis media. The incremental cost-effectiveness ratio (ICER) for observation compared with delayed prescription was \$10,000 per QALE gained. The ICER for observation compared with 5 days of antibiotic treatment was \$150,000 per QALE gained. The ICER for observation compared with 10 days of antibiotic treatment was \$350,000 per QALE gained.

Free online access!

Research essential to family medicine

The Annals of Family Medicine, a peer-reviewed clinical research journal, is dedicated to advancing knowledge essential to understanding and improving health and primary care. View the full content online at www.AnnFamMed.org, or order your print subscription online or by calling 1-800-274-2237, Ext. 5165.

ANNALS OF FAMILY MEDICINE™
www.AnnFamMed.org

Sponsors:

American Academy of Family Physicians, American Board of Family Medicine, Society of Teachers of Family Medicine, Association of Departments of Family Medicine, Association of Family Medicine Residency Directors, North American Primary Care Research Group, College of Family Physicians of Canada
 Indexed in the MEDLINE, MEDLARS, Science Citation Index Expanded, Current Contents/Clinical Medicine and PsycINFO databases. All published content deposited in PubMed Central.